The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ramucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts).
 
Ronald De Wit
Honoraria - Bayer; Janssen; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Consulting or Advisory Role - Lilly; Merck Sharp & Dohme; Roche/Genentech; Sanofi
Research Funding - Bayer (Inst); Sanofi (Inst)
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Ipsen
 
Daniel E. Castellano
Honoraria - Astellas Pharma; Janssen; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Janssen; Pfizer; Roche
Travel, Accommodations, Expenses - Ipsen; Janssen; Pfizer; Roche
 
Andrea Necchi
Honoraria - AstraZeneca; Janssen; Merck; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; BioClin Therapeutics; Clovis Oncology; Incyte; Janssen; Merck Sharp & Dohme; Roche; Seattle Genetics/Astellas
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Roche
 
Jae-Lyun Lee
Honoraria - Amgen; Astellas Pharma; Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Pfizer; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Roche/Genentech
 
Michiel Simon Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche
 
Nobuaki Matsubara
Consulting or Advisory Role - Janssen; Sanofi
Research Funding - Bayer Yakuhin (Inst); Chugai Pharma (Inst); Janssen (Inst); MSD (Inst)
 
Aristotelis Bamias
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Pierre Fabre
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - AstraZeneca; Bristol-Myers Squibb; Novartis; Pfizer; Roche; Sanofi
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Aude Flechon
No Relationships to Disclose
 
Cora N. Sternberg
Honoraria - Astellas Pharma; AstraZeneca; Ipsen; Janssen; Pfizer; Sanofi
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Eisai; Incyte; Ipsen; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Aveo (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Clovis Oncology (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Genzyme (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Myovant Sciences (Inst); Nektar (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
 
Alexandra Drakaki
Employment - Kyn therapeutics (I)
Leadership - Kyn therapeutics (I)
Stock and Other Ownership Interests - Alimera Sciences (I); UROGENE (I)
Consulting or Advisory Role - Bristol-Myers Squibb; Kyn therapeutics
Research Funding - Kite, a Gilead company
Patents, Royalties, Other Intellectual Property - 5 PATENTS AT UCLA FOR 5 POTENTIAL DRUGS (I)
Travel, Accommodations, Expenses - Lilly
 
Evan Y. Yu
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Churchill Pharmaceuticals; EMD Serono; Incyte; Janssen; Merck; QED Therapeutics; Tolmar
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Seagen (Inst)
 
Oday Hamid
Employment - Lilly; MedImmune
Stock and Other Ownership Interests - Lilly
 
Annamaria H. Zimmermann
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Ling Gao
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Amanda Long
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Richard A. Walgren
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Patents, Royalties, Other Intellectual Property - Patent applicant/holder, without royalties, for therapeutic applications related to ramucirumab and merestinib. (Inst)
 
Katherine M Bell-McGuinn
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Lilly; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi